Objective: Mutations in TPM3, encoding Tpm3.12, cause a clinically and histopathologically diverse group of myopathies characterized by muscle weakness. We report two patients with novel de novo Tpm3.12 single glutamic acid deletions at positions DE218 and DE224, resulting in a significant hypercontractile phenotype with congenital muscle stiffness, rather than weakness, and respiratory failure in one patient. Methods: The effect of the Tpm3.12 deletions on the contractile properties in dissected patient myofibers was measured. We used quantitative in vitro motility assay to measure Ca 21 sensitivity of thin filaments reconstituted with recombinant Tpm3.12 DE218 and DE224. Results: Contractility studies on permeabilized myofibers demonstrated reduced maximal active tension from both patients with increased Ca 21 sensitivity and altered cross-bridge cycling kinetics in DE224 fibers. In vitro motility studies showed a two-fold increase in Ca 21 sensitivity of the fraction of filaments motile and the filament sliding velocity concentrations for both mutations. Interpretation: These data indicate that Tpm3.12 deletions DE218 and DE224 result in increased Ca 21 sensitivity of the troponin-tropomyosin complex, resulting in abnormally active interaction of the actin and myosin complex. Both mutations are located in the charged motifs of the actin-binding residues of tropomyosin 3, thus disrupting the electrostatic interactions that facilitate accurate tropomyosin binding with actin necessary to prevent the on-state. The mutations destabilize the off-state and result in excessively sensitized excitation-contraction coupling of the contract-View this article online at wileyonlinelibrary.com.
ile apparatus. This work expands the phenotypic spectrum of TPM3-related disease and provides insights into the pathophysiological mechanisms of the actin-tropomyosin complex. ANN NEUROL 2015; 78:982-994 T ropomyosin 3 (Tpm3.12; a-tropomyosin slow), encoded by the TPM3 gene (Online Mendelian Inheritance in Man database 191030), belongs to the actin-binding tropomyosin family and is a component of the sarcomeric thin filament troponin-tropomyosin complex. Tpm3.12 is predominantly expressed in type 1 (slow twitch) fibers and forms dimers of linear coiled-coil structures with Tpm2.2 (b-tropomyosin) encoded by TPM2 and Tpm1.1 (a-tropomyosin) encoded by TPM1, which then bind head-to-tail, providing structural stability to actin filaments. 1, 2 This complex acts by regulating Ca 21 dependent binding of the myosin head to the actin filament. It serves as an essential component in the regulation of muscle contraction by preventing binding of the myosin head when in the off-state and allowing it in the on-state, in preparation for the force generating power stroke. Mutations in TPM3 recognized thus far result in a clinically and histopathologically heterogeneous group of neuromuscular disorders, which are characterized by progressive weakness and include cap myopathy, [3] [4] [5] congenital fiber type disproportion (CFTD), 6 and autosomal dominant as well as recessive nemaline myopathy. [7] [8] [9] [10] Mutations in TPM2 also typically result in a phenotype of myopathy, manifesting with weakness. However, the deletion of a single lysine residue at position 7 in Tpm2.2 can manifest clinically with both muscle weakness and moderate progressive muscle contractures. Studies of this specific mutation suggest that the pathogenic mechanism underlying some tropomyosin-related disease may be due to elevated Ca 21 sensitivity of the contractile apparatus. 11, 12 Although such a mechanism had been predicted on theoretical molecular grounds to also be applicable for Tpm3.12, 13 this phenomenon had not yet been shown conclusively to be clinically relevant. 11, 12 Here we report two unrelated patients with two distinct but closely spaced de novo Tpm3.12 single glutamic acid deletions resulting in a marked generalized hypercontractile phenotype with very significant congenital muscle stiffness, in the absence of detectable weakness, and associated with respiratory failure in the more severely affected patient. The effect of the Tpm3.12 glutamic acid deletions was studied using in vitro motility assays and mechanics on permeabilized myofibers. These deletions appear to result in impaired maximum force generation with altered cross-bridge cycling kinetics, and increased Ca 21 sensitivity of force. This study expands the phenotypic, and pathophysiological spectrum of TPM3 mutations, which now join a specific ACTA1 mutation as well as recessive ab-crystallin (CRYAB) mutations as a myogenic cause for significant neonatal muscle rigidity. 14, 15 Subjects and Methods
Patient Recruitment and Sample Collection
Two unrelated patients, one from the United States and one from Germany, were identified through their local neurologists. Medical history was obtained and clinical evaluations were performed as part of the standard neurologic evaluation. This study was approved by the institutional review board of the National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH). Written informed consent was obtained from each family by a qualified investigator. DNA was obtained from blood based on standard procedures. Muscle biopsies were obtained as part of the regular clinical diagnostic testing and were evaluated by standard light and electron microscopy protocols. Banked muscle biopsy samples were transferred to the NIH for further analysis.
Genetic Testing
Whole exome sequencing on blood samples obtained from Patient 1 (P1) and his parents was performed at the NIH Intramural Sequencing Center using the Illumina (San Diego, CA) TruSeq Exome Enrichment Kit and Illumina HiSeq 2000 sequencing instruments. Mutations were analyzed using GEM.app and xBrowse and searched for in dbSNP, NHLBI EVS, ExAC Browser, or GEM.app. 16 Polymerase chain reaction amplification of exon 6 of TPM3 in P1, Patient 2 (P2), and their parents, was followed by Sanger sequencing on an ABI 3130x1 capillary sequencer, in forward and reverse directions.
Synthesis of Tropomyosin in Sf9 Insect Cells
The wild-type (WT) human TPM3 cDNA sequence was amplified from reverse transcribed skeletal muscle RNA and then cloned into the BacPak8 plasmid (Clontech Laboratories, Mountain View, CA). The DE218 and DE224 mutations were introduced into the TPM3 cDNA by site-directed mutagenesis. The WT and two mutant tropomyosin proteins were expressed in Sf9 insect cells using the flashBAC baculovirus system (Oxford Expression Technologies, Oxford, UK). Recombinant proteins were purified using protocols based on Akkari et al. 17 
Quantitative In Vitro Motility Assay
Thin filaments were reconstituted with 10nM rabbit skeletal muscle a-actin (labeled with tetramethylrhodamine phalloidin), 18 tropomyosin (40-60nM), and skeletal troponin (60nM) to study Ca 21 regulation of filament motility by the quantitative in vitro motility assay previously described. 19, 20 Thin filament movement over a bed of immobilized rabbit fast skeletal muscle heavy meromyosin (100lg/ml) was then compared in paired motility cells with WT or mutant tropomyosin. Filament movement was recorded and analyzed as previously described, 19 yielding 2 parameters, the fraction of filaments moving and the speed of moving filaments. Fraction motile and sliding speed was measured over a range of Ca 21 concentrations to generate Ca 21 activation curves as shown previously. [20] [21] [22] [23] The temperature was set to 298C. Median effective concentration (EC 50 ) values from replicate experiments were analyzed by paired t-test, because EC 50 has been shown to be normally distributed. 20, 24 
Permeabilized Myofiber Contractile Performance
The effect of the Tpm3.12 deletion on the contractile properties in myofibers derived from patients' muscle biopsies was measured. Myofiber bundles from frozen muscle biopsies from P1 and P2 and age-matched controls were isolated as described previously. 13, 25, 26 In brief, smaller sections (2 3 2mm) of the biopsies were isolated in liquid nitrogen. They were then placed for 24 hours at 2208C in 4ml 50% glycerol/relaxing solution containing high concentrations of protease inhibitors (phenylmethylsulfonyl fluoride [PMSF], 0.5mM; leupeptin, 0.04mM; E64, 0.01mM). Subsequently, the sections were placed on a roller band for 24 hours at 48C, followed by submersion in skinning solution for 24 hours at 48C. Finally, the skinning solution was substituted by a glycerol/relaxing solution with lower concentrations of protease inhibitors and stored at 2208C until further use. On the day of an experiment, small strips (cross-sectional area [CSA] 5 0.0050.01mm 2 ) were dissected from the glycerinated sections and washed thoroughly with relaxing solution. The strips were mounted using aluminum T-clips between a length motor (ASI 403A; Aurora Scientific, Aurora, ON, Canada) and a force transducer element (ASI 315C-I, Aurora Scientific) in a skinned fiber apparatus (ASI 802D, Aurora Scientific) that was mounted on an inverted microscope (Axio Observer A1; Zeiss, Oberkochen, Germany). Sarcomere length (2.5lm) was set using a high-speed VSL camera and ASI 900B software (Aurora Scientific). Six strips were analyzed for P1 (average CSA 5 0.01mm 2 ), P2 (average CSA 5 0.005mm 2 ), and control (average CSA 5 0.006mm 2 ). Fiber width and diameter was measured at 3 points along the fiber and the CSA was determined assuming an elliptical cross section. Fiber dimensions were determined using an inverted microscope (340 objective), a high-speed VSL camera with calibrated ASI 900B software (Aurora Scientific), and a custommade prism that was mounted in the bath. DTT, 0.5mM PMSF, 0.2mM leupeptin, 0.05mM E64), and activating solutions with incremental Ca 21 concentrations for graded Ca 21 response curves (40mM BES, 10mM CaCO 3 -EGTA [for maximal activation]; 6.64mM MgCl 2 , 6.23mM Na-ATP, 2.1mM K-propionate, 15mM creatine phosphate, 1mM DTT, 0.5mM PMSF, 0.2mM leupeptin, 0.05mM E64). The temperature of the bathing solutions was kept constant at 208C using a temperature controller (ASI 825A, Aurora Scientific).
Absolute forces were normalized to the bundles' CSA to determine the maximal active tension. To determine the Ca 21 sensitivity of force generation, permeabilized myofiber bundles were sequentially bathed in a relaxing solution, a preactivation solution, and solutions with pCa values ranging from 9.0 to 4.5. Steady-state forces were measured at all the Ca 21 concentrations, and subsequently these steady-state values were normalized to the maximal force obtained at pCa 5 4.5. The obtained force-pCa data were fit to the Hill equation (Y 5 1/ [1 1 10n H (pCa 2 pCa 50 )]). Cross-bridge cycling kinetics were determined by imposing a rapid release-restretch protocol on an activated fiber based on previously reported methods. 27 The rate of tension redevelopment was obtained by fitting a biexponential through the force redevelopment curve. The resulting first-order rate constant k 1 reflects cross-bridge cycling kinetics and thus was used in the analysis methods. 28 A measure of active stiffness was obtained by applying short-length perturbations on the myofibers, while the myofibers were being maximally activated, and fit to a linear curve through the data points. By dividing the maximal active tension by active stiffness, the force generation per cross-bridge was estimated. 29 
Myosin Heavy Chain Isoform Composition of Myofibers Used for Contractility Experiments
Because the contractile performance of muscle fibers is affected by the composition of myosin heavy chain isoforms, we used specialized sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis to determine the myosin heavy chain isoforms present in the muscle fibers used for contractile measurements. 25 In brief, muscles fibers were denatured by boiling for 2 minutes in SDS sample buffer. The stacking gel contained a 4% acrylamide concentration (pH 5 6.7), and the separating gel contained 7% acrylamide (pH 5 8.7) with 30% glycerol (vol/vol). The gels were run for 24 hours at 158C and a constant voltage of 275V. Finally, the gels were silver-stained, scanned, and analyzed with One-D scan EX (Scanalytics, Rockville, MD) software (data not shown).
Results

Clinical Assessment Identified two Patients with a Significant Hypercontractile Phenotype with Marked Congenital Muscle Stiffness
We identified two patients with a history of marked congenital muscle stiffness, which was most significant at the onset. Detailed clinical information is summarized in the Table and Figure 1 . P1 is a 5-year-old male (see Fig 1A, B ). Pregnancy was notable for decreased fetal movements but normal amniotic fluid level. He was born with arthrogryposis multiplex congenita with bilateral contractures of the hips, knees, and wrists. He also had bilateral hand fisting, right clubfoot deformity, unilateral hip dislocation, an inguinal hernia, and generalized muscle stiffness. Neonatal course was complicated by transient respiratory distress, particularly during feeding, manifesting with an increased respiratory rate. He also had a history of low oxygen saturations and occasional grunting at rest as a neonate. He rolled from his back to his side at 6 months of age, could manipulate objects in his hands and bring some objects to his mouth by 15 months of age, and walked independently at 25 months of age. He had notable easy fatigability.
On examination at age 4 years, he had a "wooden feel" to his muscles, which were noted to be very stiff, particularity the hamstrings, the paraspinal muscles, and the face muscles. He had well-defined biceps and prominent thigh muscles. There was no muscle weakness noted. Deep tendon reflexes were intact. He had good fine motor control. Active and passive range of motion was restricted at his shoulders, Achilles tendons, elbows, knees, and jaw. He walked on his toes with a stiff, shuf-fling gait with almost no flexion at the knees or hips appreciated (Supplementary Video). Due to restricted movement at these joints, he could not reach his arms above his head. He had excessive thoracic kyphosis, with a minimal scoliosis, and rigidity of the lower spine. He had short stature with height below the 5th percentile, weight along the 10th percentile, and head circumference along the 50th percentile.
He had a history of inappropriate sweating and was reported to be prone to "overheating" particularly at night during sleep. His muscle stiffness was reported to exacerbate with movement or fatigue and improve with the application of warm water. He had a history of dysphagia and evidence of silent aspiration of liquids on videofluoroscopy. He also had a history of frequent episodes of bronchiolitis. He had been diagnosed with restrictive lung disease and uses a Cough Assist device to help improve expiratory function. A sleep study revealed evidence of hypoventilation. He has been advised to use nighttime noninvasive ventilation in the form of bilevel positive airway pressure (BiPAP), but he could not tolerate the BiPAP mask. After the time of our examination, he received two courses of botulinum toxin injections to the hamstrings and pectoral muscles in an effort to improve his range of motion. He was then able to reach his arms above his head and walk with more fluidity by 5 years of age. Diagnostic testing performed on P1 included electromyography (EMG) at age 6 months of age, which was interpreted as being myopathic with denervating features. Continuous motor unit activity in the form of myotonia and myokymia were not observed.
P2 is a 3-year-old female (see Fig 1C) . The pregnancy was notable for polyhydramnios and decreased fetal movement. She was born at term and presented with severe, generalized muscle stiffness immediately after birth. Flexion muscle contractures were present in all large joints, which resulted in an inability for active or passive movements. Apparent involvement of the respiratory muscles contributed to recurrent episodes of apnea that led to the need for invasive ventilation with high inspiratory pressures (up to 40cm H 2 O). Treatment with carbamazepine, benzodiazepines, and baclofen reportedly provided no substantial benefit. Due to continuing ventilatory dependency, a tracheostomy was placed. She also had a percutaneous gastrostomy tube placed for feeding. She was discharged from the hospital at the age of 5 months. At the current age of 3 years, she remains fully ventilator-dependent with high inspiratory pressures (up to 25cm H 2 O). On examination, she had normal eye movements and appeared mentally alert. Muscle tone was markedly increased, with absent deep tendon reflexes. She demonstrated the ability to use a standing frame, but had difficulty sitting due to apparent hyperactivity of her hip extensors.
Muscle tone reportedly reduced slightly after intramuscular injections of botulinum toxin, and some limited voluntary movements were appreciated. She has started to use an assistive communication device. Extensive diagnostic evaluations including brain magnetic resonance imaging, electroencephalography, and metabolic screening did not reveal any abnormalities. Serum creatine kinase (CK) levels varied between 200 and 1,000U/ l. EMG did not show evidence of myotonia or myokymia. Muscle ultrasound depicted markedly increased echogenicity of all muscles imaged but no evidence of muscle atrophy.
Exome Analysis Identified two Novel De Novo Glutamic Acid Residue Deletions in Tpm3.12
Whole exome sequencing of P1 and both biological parents followed by variant filtering for call quality and rarity yielded a heterozygous c.673-675delGAA (p.Glu224del, DE224) TPM3 variant (reference NM_152263.3). Due to phenotypic similarity noted between P1 and P2, this region was Sanger sequenced in P2, revealing a heterozygous 3 base pair deletion c.657_659delAGA (p.Glu218-del, DE218), resulting in the deletion of glutamic acid at amino acid 218 (Fig 2A, B) . Parental segregation studies for P1 and P2 were negative; the mutation was de novo in both patients. Neither mutation had been previously reported, and neither was present in dbSNP, NHLBI EVS, ExAC Browser, or GEM.app. 16 Both mutations are located in highly conserved regions of TPM3 (see Fig 2C, D) .
Tpm3.12 DE218 and DE224 Muscle Biopsies Did Not Show Typical Tropomyosin Pathology
Muscle biopsy of P1 was performed at age 17 months and was mildly myopathic in appearance without specific features. There was mild variation in fiber size and a mild type I fiber predominance (Fig 3) . Nicotinamide adenine dinucleotide (NADH) staining demonstrated irregular staining in some fibers resulting in some areas of clearing. Modified G€ om€ ori trichrome stain demonstrated irregularities of the myofibrillar apparatus. There was no evidence of clear nemaline rods or a pattern consistent with CFTD. There was ultrastructural evidence of accumulation of mitochondria, increased lipid storage, and Z-line streaming and broadening, which was focal, occurring in rare fibers, and spanning up to 6 to 7 sarcomeres maximally, seen on electron microscopy (EM) along with some sarcolemmal folding as a result of fiber atrophy.
Muscle biopsy of P2 was performed at age 3 weeks and demonstrated mild myopathic features. Findings included mild variation in fiber size and some rare basophilic fibers with centrally placed nuclei (see Fig 3) . There was mild type II fiber predominance seen on ATPase and NADH staining but no fiber-type grouping. Structures resembling minirods were identified on EM as well as some Z-band broadening in atrophic fibers. Whereas clearly formed nemaline rods were not seen on modified G€ om€ ori trichrome stain or EM, mini "miliary" rods were seen in small atrophic fibers both on modified G€ om€ ori trichrome stain and on EM.
Increased Ca 21 Sensitivity for Tpm3.12 DE218 and DE224 by In Vitro Motility Assay Using the in vitro motility assay, the movement of synthetic thin filaments containing recombinant WT or mutant tropomyosin (Tpm3.12 DE218 and DE224) was compared over a range of Ca 21 concentrations. This assay measures two parameters that are Ca 21 regulated: fraction of filaments motile and sliding speed of the filaments. Ca 21 increased the fraction motile from 2% to 90% and the sliding speed from 1.3 to 4lm/s. The EC 50 and Hill coefficient (n H ) were determined by fitting the Hill equation to the Ca 21 activation curves. The mutations affected both the fraction motile and the sliding speed of the filaments in a similar way. Thin filaments reconstituted with mutant tropomyosins showed a higher Ca 21 sensitivity for both the fraction motile and the sliding speed; representative Ca 21 activation curves are shown in Figure 4 . DE218 led to a 2 1 = 2 -fold increase in Ca 21 sensitivity (EC 50 ratio 5 DE218/WT 5 0.40 6 0.07, p 5 0.004, n 5 4) for the fraction motile and a 2-fold increase for the sliding speed (EC 50 ratio 5 DE218/WT 5 0.48 6 0.12, p 5 0.02, n 5 4). DE224 also showed an increase in Ca 21 sensitivity in the fraction motile and the sliding speed parameter by 2.2-and 3.0-fold, respectively (EC 50 ratio 5 DE224/WT for fraction motile 5 0.46 6 0.09, p 5 0.01, n 5 4; EC 50 ratio 5 DE224/WT for sliding speed 5 0.33 6 0.08, p 5 0.004, n 5 4), indicating that both mutations cause a gain of function. There was no significant difference in the maximum fraction motile, maximum sliding speed, or Hill coefficient between either of the mutants and the WT thin filaments. DE218 and DE224 Permeabilized Myofibers Showed Decreased Maximum Force Generation and DE218 Showed Increased Ca 21 Sensitivity with Reduced Cross-Bridge Cycling Kinetics Contractile properties of permeabilized myofibers isolated from biopsies from P1 and P2 (DE224 and DE218) were measured. The maximal active tension in DE218 (31 6 5 mN/mm 2 ) and DE224 (35 6 2 mN/mm 2 ) permeabilized myofibers showed a significant decrease in maximum force generation compared to controls (95 6 14 mN/mm 2 ; Fig 5) . The Ca 21 sensitivity of force generation in DE224 (5.94 6 0.02) was increased compared to control fibers (5.81 6 0.02). The maximum force a muscle fiber can generate is dependent on the rate of cross-bridge cycling kinetics. The rate constant of force redevelopment (Ktr) is a widely used parameter of crossbridge cycling kinetics, reflecting both cross-bridge attachment and detachment. Analysis showed that cross-bridge cycling kinetics are reduced in Tpm3.12 DE224 (6.1 6 1) compared to control myofibers (9.8 6 1), whereas maximal active tension over active stiffness, a reflection of the force per cross-bridge, was not altered between Tpm3.12 DE224 (2.2 6 0.1) and control fibers (2.2 6 0.1). Unfortunately, due to technical limitations caused by lower quality and quantity of the biopsy, we could not measure cross-bridge cycling kinetics and force per cross-bridge in Tpm3.12 DE218.
As the contractile performance of myofibers is dependent on the myosin heavy chain (MHC) isoform composition, the presence of MHC isoforms was determined. No significant changes between control myofibers (27 6 6% slow MHC and 73 6 6% fast MHC) and DE218 (30 6 5% slow MHC and 66 6 6% fast MHC) or DE224 (20 6 7% slow MHC and 80 6 7% fast MHC) were found. Therefore, the changes observed in contractile performance between control and patient 
Discussion
Muscle fiber-based stiffness, in the absence of clinically detectable weakness, is a rare manifestation of congenital muscle disease. It was originally reported in Canadian aboriginal patients with a fatal condition characterized by progressive muscle stiffness and respiratory insufficiency 15 due to recessive mutations in CRYAB. CRYAB codes for the small chaperone ab-crystallin; however, the mechanism responsible for the muscle stiffness remains unclear. Additionally, a specific de novo mutation in ACTA1 was found in a newborn with congenital episodic stiffness, hypertrophic muscles, and nemaline rod muscle pathol-ogy. 14 Our report is the first to demonstrate specific TPM3 deletions as the cause of a novel phenotypic manifestation of marked and generalized congenital muscle stiffness. This phenotype is notable for an absence of muscle weakness in combination with muscle stiffness, which is so severe that it can result in early ventilatory failure, likely due to an incapacity for respiratory muscle relaxation, as evidenced by the high inspiratory pressures required during mechanical ventilation in P2.
The muscle thin filament is a cooperative/allosteric system. Its basic unit consists of a backbone of actin monomers, the troponin-tropomyosin complex, and nebulin. 24 Muscle contraction is regulated by Ca 21 via its release and reuptake from the sarcoplasmic reticulum. Ca 21 binding to troponin C on the thin filaments of muscle results in switching contraction from the "off" to the "on" state by causing a sideward shift of the actinbinding tropomyosin dimer, exposing the myosin binding site on the actin filament. [30] [31] [32] Tropomyosins thus play a vital role in transmitting the Ca 21 signal from the troponin to the actin myosin binding site. Mutations in TPM3 (coding for Tpm3.12) are an established molecular cause of a clinically and histopathologically heterogeneous group of myopathies, characterized by progressive weakness and by variable but characteristic findings on muscle pathology including nemaline rods, CFTD, or cap-like structures. The phenotype associated with Tpm3.12 DE218 and DE224, with its congenital stiffness resulting from marked muscle hypercontractility, is significantly different from these known manifestation of TPM3-related disease. Muscle biopsy analysis did not reveal the typical muscle pathology seen in tropomyosinrelated disease, including clear nemaline rods, although small rod-like structures ("miliary rods") were seen in atrophic fibers of P2. We also found evidence of myofiber damage histologically, likely due to the permanently hypercontracted state of the muscle fibers, consistent with increased CK values. Six TPM2 and 1 TPM3 mutation that result in increased Ca 21 sensitivity have been reported in patients with only moderately progressive contractures and myopathic weakness. 11, 12, 33 In contrast, our patients presented with a distinctive and considerably more severe congenital hypercontractile phenotype with generalized muscle stiffness leading to severe respiratory failure in the neonatal period in one patient which represents a novel phenotype for tropomyosin-related disease.
Mutations in tropomyosin or actin that produce a hypercontractile phenotype may destabilize the "switched off" state, shifting the equilibrium in favor of the "switched on" state of actin-tropomyosin, which allows for myosin binding, thereby increasing Ca 21 sensitivity and, in one case, increasing maximum force generated and cross-bridge cycling rate. 11, 14, 34, 35 The finding that the Tpm3.12 DE218 and DE224 mutations introduced into recombinantly expressed tropomyosin resulted in increased Ca 21 sensitivity in the in vitro motility assay (see Fig 4) , and that the Tpm3.12 DE224 biopsy has increased Ca 21 sensitivity of force production (see Fig  5) , is compatible with this mechanism as the basis of the hypercontractile phenotype.
The hypercontractile phenotype associated with these Tpm3.12 mutations also conforms to the predictions made by Marston et al 22 on biophysical grounds (Fig 6) , which we now confirm clinically as well as in vitro. The atomic resolution structure of tropomyosinbound actin shows that tropomyosin makes contact with actin at only two points: with actin Asp25 and with a cluster of basic amino acids actin K326, K328, and R147. 36 Tropomyosin has a seven-fold repeated structure corresponding to seven actin-binding interactions. Three 32 Surface rendering was made using PyMol. Actin K326, K328, and R147 are shown in different shades of blue, and tropomyosin 218, 219, 223, and 224 are shown in magenta. (C) The interface of tropomyosin period 6 with actin. Actin K326, K328, and R147 are shown in different shades of blue, E218 and E224 are shown in red, and D219 and E223 are shown in pink. Actin is represented by surface rendering; the secondary structure of tropomyosin backbone (coiled-coil alpha helix) is shown with the side chains in line notation.
Tpm2.2 mutations and the Tpm3.12 mutation K169E were shown to destabilize the interaction with actin Asp25, based on energy landscape calculations, and increase Ca 21 sensitivity in in vitro motility assay, consistent with gain of contractile function. 22, 37 More importantly, two Tpm2.2 mutations, DE139 and E181K, destabilize the interaction with the actin K326, K328, and R147 cluster. All of these mutations involve a charge loss or reversal in a motif of two basic or acidic amino acids. There are nine such motifs in all tropomyosin isoforms. Mutations have been described in myopathy patients with increased in vitro Ca 21 sensitivity for six of the nine motifs (five in Tpm2.2 and one in Tpm3.12, 3 of which were associated with a phenotype of arthrogryposis or some signs of stiffness or contractures in addition to weakness). The remaining three motifs are at 218-219 (ED), 223-224 (EE), and 257-258 (ED) in either tropomyosin. 22 Thus, the "stiff" patients' mutations reported here are in the first two of these three remaining domains, which were predicted to result in a hypercontractile state. It is striking that the hypercontractile consequences in our cases are clinically more pronounced compared to the manifestations of other tropomyosin mutations previously reported. Notably, most of the mutations tested in vitro and found to display increased Ca 21 sensitivity are located adjacent to the tropomyosin amino acid that interacts with actin rather than at the site itself. 22 This also applies to Tpm3.12 E218 and E224, which do not interact with actin, whereas neighboring Tpm3.12 E219 and E223 interact directly with the actin K326, K328, and R147 cluster (see Fig 6) . In light of the structural analysis modeling of these physical interactions, it is significant that the actin K326N mutation at the cognate site in actin itself was the first "stiff" patient mutation reported in a thin filament protein. 14, 22, 38 The degree of stiffness seen in that patient appeared similar to our observation. 14 The in vitro sliding data obtained with mutant protein provide the link crucial to understanding the clinical hypercontractile phenotype; however, the consequences of the mutation on the entire thin filament and contractile fiber show additional complexities. Notably, the skinned fiber preparation had decreased maximal active tension resulting in a decrease in maximal force generation, whereas the force per cross-bridge was not altered. This raises the possibility that the cycling of cross-bridges back into the "off" state is impaired. The observed reduction in rate constant of force redevelopment, which indicates a reduced effectiveness of cross-bridge cycling, could explain the impaired force generation capacity of the muscle. Muscle fibers from P1 (DE224) generated a higher relative force at the same Ca 21 concentration, which may there-fore compensate for the loss of maximal force-generating capacity. Because there was no evidence of weakness in the patients (at the time of examination), we surmise that the hypercontractility at submaximal calcium concentrations is so overwhelming that any decrease in maximal force does not come to bear on the phenotype. The continuous cellular stress of the hypercontractility of the muscle may cause future muscle damage and breakdown in our patients, possibly resulting in weakness and findings of tropomyosin muscle pathology over time. This assumption is supported by the CK elevations and also by the markedly abnormal muscle ultrasound findings in P2.
The question remains as to why the stiffness phenotype in our patients is significantly more severe and generalized compared to the best characterized gain of function mutation in Tpm2.2, the DK7 deletion, identified in patients with progressive, early onset contractures without clear muscle weakness in childhood but with some stiffness noted in one 14-year-old boy. 11 Tpm2.2 is expressed in both fast-and slow-twitch fibers. Increased Ca 21 sensitivity of force generation has also been observed in patients with distal arthrogryposis caused by mutations in troponin I (TNNI2) and troponin T3 (TNNT3), encoding for contractile apparatus proteins specific to fast-twitch fibers. 39 Contractures due to distal muscle involvement, which are predominantly fast-twitch fibers, typically develop prenatally but have little to no progression over time, with relatively normal proximal muscle strength and histology. 40 The generalized and more severe congenital stiffness observed in the Tpm3.12 DE218 and DE224 patients may thus be partially related to the expression pattern, with Tpm3.12 being the most relevant tropomyosin for all slow-twitch fibers.
Finally, we considered how the molecular mechanisms reported here could inform a rational therapeutic approach to these patients. P1 showed improvement with botulinum toxin injections, leading to increased range of motion, improved gait, and increased jaw mobility with enhanced speech production. Decreased neuromuscular transmission from the botulinum application would lead to less activation of excitation-contraction coupling, likely taking the edge off the baseline hypercontractility associated with the underlying TPM3 mutation. Given the growing amount of literature supporting changed Ca 21 sensitivity of the actin-tropomyosin complex as a mechanism for muscle disease, future therapeutic strategies may involve reducing the release of Ca 21 at the sarcomere. An alternative approach would be to desensitize the thin filament to Ca 21 . In cases of decreased Ca 21 sensitivity, compounds that act as Ca 21 sensitizers, which are under active development in the neuromuscular and heart failure field, may be utilized. 39, 40 The latter type of approach would likely be detrimental in the patients reported here.
In conclusion, in this study we identified two patients with a marked congenital hypercontractile phenotype caused by dominantly acting de novo mutations in Tpm3.12, DE218 and DE224, representing the most severe tropomyosin-related hypercontractile phenotype recognized to date. Our experiments confirm a mechanism of increased Ca 21 sensitivity by which Tpm3.12 mutant muscle fibers contract at lower Ca 21 concentrations compared to WT fibers. Our data lend in vivo and in vitro support to the conclusion that the increased Ca 21 sensitivity observed for both DE218 and DE224 results from a destabilization of the "off" state of the thin filament, resulting in excessively sensitized excitation-contraction coupling of the contractile apparatus, as previously predicted for DE218 on theoretical biophysical grounds. Mutations in tropomyosin, specifically in TPM3, should therefore be considered when evaluating a patient with congenital-onset muscle stiffness.
